

The role of Shp2 (PTPN11) in cancer

Current Opinion in Genetics and Development

17, 23-30

DOI: [10.1016/j.gde.2006.12.011](https://doi.org/10.1016/j.gde.2006.12.011)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Shp2E76K Mutant Confers Cytokine-independent Survival of TF-1 Myeloid Cells by Up-regulating Bcl-XL. <i>Journal of Biological Chemistry</i> , 2007, 282, 36463-36473.	1.6	15
2	Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 621-640.	2.2	211
3	Hyperactive Ras in developmental disorders and cancer. <i>Nature Reviews Cancer</i> , 2007, 7, 295-308.	12.8	1,422
4	Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia. <i>Cell Research</i> , 2007, 17, 295-297.	5.7	15
5	A Brake Becomes an Accelerator: PTP1B A New Therapeutic Target for Breast Cancer. <i>Cancer Cell</i> , 2007, 11, 214-216.	7.7	86
6	Targeting PTPs with small molecule inhibitors in cancer treatment. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 263-272.	2.7	119
7	PTPL1: a large phosphatase with a split personality. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 205-214.	2.7	57
8	Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 193-203.	2.7	12
9	The tyrosine phosphatase Shp2 (PTPN11) in cancer. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 179-192.	2.7	343
10	Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations. <i>International Journal of Hematology</i> , 2008, 88, 287-290.	0.7	8
11	The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. <i>Human Mutation</i> , 2008, 29, 992-1006.	1.1	322
12	Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. <i>FEBS Journal</i> , 2008, 275, 816-830.	2.2	64
13	Role of SHP2 for FLT3-dependent proliferation and transformation in 32D cells. <i>Leukemia</i> , 2008, 22, 1945-1948.	3.3	15
14	Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. <i>Oncogene</i> , 2008, 27, 3508-3515.	2.6	92
15	Linking epithelial polarity and carcinogenesis by multitasking <i>Helicobacter pylori</i> virulence factor CagA. <i>Oncogene</i> , 2008, 27, 7047-7054.	2.6	67
16	Ras oncogenes: split personalities. <i>Nature Reviews Molecular Cell Biology</i> , 2008, 9, 517-531.	16.1	1,267
17	Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. <i>Cancer Science</i> , 2008, 99, 1319-1325.	1.7	224
18	The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. <i>Cellular Signalling</i> , 2008, 20, 453-459.	1.7	275

#	ARTICLE	IF	CITATIONS
19	Bench to bedside and back again: Molecular mechanisms of β -catenin function and roles in tumorigenesis. <i>Seminars in Cancer Biology</i> , 2008, 18, 53-64.	4.3	106
20	Protein Tyrosine Phosphatases in Autoimmunity. <i>Annual Review of Immunology</i> , 2008, 26, 29-55.	9.5	164
21	Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4948-4956.	2.9	83
22	SagA of CagA in Helicobacter pylori pathogenesis. <i>Current Opinion in Microbiology</i> , 2008, 11, 30-37.	2.3	119
23	Genetic approaches for changing the heart and dissecting complex syndromes. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 148-155.	0.9	11
24	A2 isoform of mammalian translation factor eEF1A displays increased tyrosine phosphorylation and ability to interact with different signalling molecules. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 63-71.	1.2	51
26	SHP-2 is a novel target of Abl kinases during cell proliferation. <i>Journal of Cell Science</i> , 2008, 121, 3335-3346.	1.2	42
27	Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7275-7280.	3.3	199
28	A Transgenic Drosophila Model Demonstrates That the Helicobacter pylori CagA Protein Functions as a Eukaryotic Gab Adaptor. <i>PLoS Pathogens</i> , 2008, 4, e1000064.	2.1	66
29	Innovative Leukemia and Lymphoma Therapy. , 0, , .		0
30	Regulation of RhoA-dependent ROCKII activation by Shp2. <i>Journal of Cell Biology</i> , 2008, 181, 999-1012.	2.3	50
31	Synapses are regulated by the cytoplasmic tyrosine kinase Fer in a pathway mediated by p120catenin, Fer, SHP-2, and β -catenin. <i>Journal of Cell Biology</i> , 2008, 183, 893-908.	2.3	46
32	Animal Models for Noonan Syndrome and Related Disorders. <i>Monographs in Human Genetics</i> , 2008, , 138-150.	0.5	0
33	Protein tyrosine phosphatases in the JAK/STAT pathway. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 4925.	3.0	241
34	Article Commentary: Should We Consider Cancers as Embryonic Diseases or as Consequences of Stem-Cell Deregulation?. <i>Clinical Medicine Oncology</i> , 2008, 2, CMO.S603.	0.2	1
35	Elevated Expression of the Tyrosine Phosphatase SHP-1 Defines a Subset of High-Grade Breast Tumors. <i>Oncology</i> , 2009, 77, 378-384.	0.9	35
36	Hepatocyte growth factor (HGF) signals through SHP2 to regulate primary mouse myoblast proliferation. <i>Experimental Cell Research</i> , 2009, 315, 2284-2292.	1.2	34
37	Novel phosphotyrosine targets of FGFR2IIIb signaling. <i>Cellular Signalling</i> , 2009, 21, 1370-1378.	1.7	28

#	ARTICLE	IF	CITATIONS
38	The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment. Expert Opinion on Therapeutic Targets, 2009, 13, 689-700.	1.5	34
39	Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood, 2009, 113, 4414-4424.	0.6	107
40	Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells. Current Stem Cell Research and Therapy, 2009, 4, 9-15.	0.6	61
41	The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. Genes and Cancer, 2010, 1, 1200-1210.	0.6	88
42	Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas. Digestive Diseases and Sciences, 2010, 55, 1565-1569.	1.1	25
43	Transcriptome and expression profiling analysis revealed changes of multiple signaling pathways involved in immunity in the large yellow croaker during <i>Aeromonas hydrophila</i> infection. BMC Genomics, 2010, 11, 506.	1.2	141
44	Noonan syndrome, the <i>SOS1</i> gene and embryonal rhabdomyosarcoma. Genes Chromosomes and Cancer, 2010, 49, 635-641.	1.5	33
45	Phosphatase inhibitors with anti-angiogenic effect <i>in vitro</i> . Apmis, 2010, 118, 49-59.	0.9	8
46	miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). British Journal of Cancer, 2010, 103, 877-884.	2.9	141
47	SH2 Domain-Containing Protein-Tyrosine Phosphatases. , 2010, , 771-809.		14
48	Prolactin Enhances Insulin-like Growth Factor I Receptor Phosphorylation by Decreasing Its Association with the Tyrosine Phosphatase SHP-2 in MCF-7 Breast Cancer Cells. Journal of Biological Chemistry, 2010, 285, 8003-8012.	1.6	22
49	Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor-Activating Mutations. Cancer Research, 2010, 70, 3843-3850.	0.4	55
50	High concentrations of HGF inhibit skeletal muscle satellite cell proliferation <i>in vitro</i> by inducing expression of myostatin: a possible mechanism for reestablishing satellite cell quiescence <i>in vivo</i> . American Journal of Physiology - Cell Physiology, 2010, 298, C465-C476.	2.1	86
51	Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome Pathogenesis. Developmental Cell, 2010, 18, 750-762.	3.1	96
52	Nrg1/ErbB signaling networks in Schwann cell development and myelination. Seminars in Cell and Developmental Biology, 2010, 21, 922-928.	2.3	207
53	Approaches to the Identification of Protein Tyrosine Phosphatase Substrates. , 2010, , 717-725.		0
54	Rasopathies: Developmental Disorders That Predispose to Cancer and Skin Manifestations. Actas Dermo-sifiliogrÁficas, 2011, 102, 402-416.	0.2	19
55	Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nature Genetics, 2011, 43, 679-684.	9.4	260

#	ARTICLE	IF	CITATIONS
56	Substrate Specificity of Protein Tyrosine Phosphatases 1B, RPTP β , SHP-1, and SHP-2. <i>Biochemistry</i> , 2011, 50, 2339-2356.	1.2	87
58	SHP2 Tyrosine Phosphatase Converts Parafibromin/Cdc73 from a Tumor Suppressor to an Oncogenic Driver. <i>Molecular Cell</i> , 2011, 43, 45-56.	4.5	97
59	Tyrosine Phosphatases in the HER2-Directed Motility of Ovarian Cancer Cells: Involvement of PTPN12, ERK5 and FAK. <i>Analytical Cellular Pathology</i> , 2011, 34, 101-112.	0.7	23
60	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome β “positive cells derived from patients with chronic myeloid leukemia. <i>Blood</i> , 2011, 118, 3634-3644.	0.6	46
61	Inside the human cancer tyrosine phosphatome. <i>Nature Reviews Cancer</i> , 2011, 11, 35-49.	12.8	427
62	Shp2 suppresses PyMT-induced transformation in mouse fibroblasts by inhibiting Stat3 activity. <i>Virology</i> , 2011, 409, 204-210.	1.1	9
63	Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6833-6837.	1.0	17
64	High-Throughput Methods in Identification of Protein Tyrosine Phosphatase Inhibitors and Activators. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 141-150.	0.9	12
65	The p75 receptor mediates axon growth inhibition through an association with PIR-B. <i>Cell Death and Disease</i> , 2011, 2, e198-e198.	2.7	48
66	Identification of PTP β as an autophagic phosphatase. <i>Journal of Cell Science</i> , 2011, 124, 812-819.	1.2	50
67	Potential of Helicobacter pylori CagA Protein Virulence through Homodimerization. <i>Journal of Biological Chemistry</i> , 2011, 286, 33622-33631.	1.6	32
68	Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 4-18.	0.9	37
69	Expression and Clinical Significance of SHP2 in Gastric Cancer. <i>Journal of International Medical Research</i> , 2012, 40, 2083-2089.	0.4	34
70	Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia. <i>Blood</i> , 2012, 119, 4228-4241.	0.6	20
71	Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice. <i>Blood</i> , 2012, 120, 1888-1898.	0.6	4
72	Tertiary Structure-Function Analysis Reveals the Pathogenic Signaling Potentiation Mechanism of Helicobacter pylori Oncogenic Effector CagA. <i>Cell Host and Microbe</i> , 2012, 12, 20-33.	5.1	139
73	Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression. <i>Cell Communication and Signaling</i> , 2012, 10, 19.	2.7	38
74	Inhibition of SHP-2 Activity by PRL-3 Inhibitor I. <i>Bulletin of the Korean Chemical Society</i> , 2012, 33, 4277-4279.	1.0	0

#	ARTICLE	IF	CITATIONS
75	Protein Tyrosine Phosphatases in Cancer. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 106, 253-306.	0.9	65
76	Shp2 Activates Fyn and Ras to Regulate RBL-2H3 Mast Cell Activation following Fc β RI Aggregation. <i>PLoS ONE</i> , 2012, 7, e40566.	1.1	16
77	Novel Functions of the Phosphatase SHP2 in the DNA Replication and Damage Checkpoints. <i>PLoS ONE</i> , 2012, 7, e49943.	1.1	19
78	SHP-2 and PTP-pest induction during Rb-E2F associated apoptosis. <i>Cellular and Molecular Biology Letters</i> , 2012, 17, 422-32.	2.7	4
79	Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline <i>PTPN11</i> mutation p.E139D. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 652-658.	0.7	10
80	Protein Tyrosine Phosphatases: Structure, Function, and Implication in Human Disease. <i>Methods in Molecular Biology</i> , 2013, 1053, 179-221.	0.4	104
81	Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 1673-1696.	1.8	90
82	YAP and TAZ, Hippo Signaling Targets, Act as a Rheostat for Nuclear SHP2 Function. <i>Developmental Cell</i> , 2013, 26, 658-665.	3.1	88
83	Age-Dependent Germline Mosaicism of the Most Common Noonan Syndrome Mutation Shows the Signature of Germline Selection. <i>American Journal of Human Genetics</i> , 2013, 92, 917-926.	2.6	46
84	eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 933-944.	1.7	50
85	Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14924-14929.	3.3	85
86	XAF1 contributes to dengue virus-induced apoptosis in vascular endothelial cells. <i>FASEB Journal</i> , 2013, 27, 1062-1073.	0.2	32
87	SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells. <i>Clinical Cancer Research</i> , 2013, 19, 798-808.	3.2	70
88	Src homology phosphotyrosyl phosphatase expression is an independent negative prognostic factor in human breast cancer. <i>Histopathology</i> , 2013, 63, 74-82.	1.6	13
89	Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis. <i>Scientific Reports</i> , 2013, 3, 2845.	1.6	27
90	Protein Tyrosine Phosphatases PTP-1B, SHP-2, and PTEN Facilitate Rb/E2F-Associated Apoptotic Signaling. <i>PLoS ONE</i> , 2014, 9, e97104.	1.1	9
91	Tyrosine Phosphatase Shp2 Mediates the Estrogen Biological Action in Breast Cancer via Interaction with the Estrogen Extranuclear Receptor. <i>PLoS ONE</i> , 2014, 9, e102847.	1.1	23
92	Oncogenic Shp2 disturbs microtubule regulation to cause HDAC6-dependent ERK hyperactivation. <i>Oncogene</i> , 2014, 33, 2938-2946.	2.6	23

#	ARTICLE	IF	CITATIONS
93	Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies. <i>Cell Cycle</i> , 2014, 13, 2827-2835.	1.3	24
94	Targeted Disruption of <i>Shp2</i> in Chondrocytes Leads to Metachondromatosis With Multiple Cartilaginous Protrusions. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 761-769.	3.1	47
95	The Transition from Stem Cell to Progenitor Spermatogonia and Male Fertility Requires the SHP2 Protein Tyrosine Phosphatase. <i>Stem Cells</i> , 2014, 32, 741-753.	1.4	38
97	Shp2-Dependent ERK Signaling Is Essential for Induction of Bergmann Glia and Foliation of the Cerebellum. <i>Journal of Neuroscience</i> , 2014, 34, 922-931.	1.7	38
98	Design of specific inhibitors of the protein tyrosine phosphatase SHP-2 by virtual screening and core hopping method. <i>Molecular Simulation</i> , 2014, 40, 904-911.	0.9	3
99	Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis. <i>BMC Cancer</i> , 2014, 14, 442.	1.1	32
100	Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 285-290.	2.5	29
101	Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 117, 234-242.	0.2	27
102	Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. <i>Blood</i> , 2014, 124, 2487-2497.	0.6	98
103	Functions of Shp2 in cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 2075-2083.	1.6	196
104	Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2. <i>Scientific Reports</i> , 2015, 5, 17626.	1.6	39
105	Direct Chemical Activation of a Rationally Engineered Signaling Enzyme. <i>ChemBioChem</i> , 2015, 16, 1735-1739.	1.3	4
106	Strategies to make protein serine/threonine (PP1, calcineurin) and tyrosine phosphatases (PTP1B) druggable: Achieving specificity by targeting substrate and regulatory protein interaction sites. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2781-2785.	1.4	33
108	Genetic variation in C12orf51 is associated with prognosis of intestinal-type gastric cancer in a Chinese population. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 133-138.	2.5	8
109	Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2. <i>Biochemistry</i> , 2015, 54, 497-504.	1.2	51
110	Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. <i>Leukemia</i> , 2015, 29, 1290-1300.	3.3	50
111	MKP-3 regulates PDGF-BB effects and MAPK activation in meningioma cells. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 752-757.	0.8	7
112	EGF augments TGF β -induced epithelial-mesenchymal transition by promoting SHP2 binding to GAB1. <i>Journal of Cell Science</i> , 2015, 128, 3898-909.	1.2	49

#	ARTICLE	IF	CITATIONS
113	Xenopus laevis FGF receptor substrate 3 (XFrs3) is important for eye development and mediates Pax6 expression in lens placode through its Shp2-binding sites. <i>Developmental Biology</i> , 2015, 397, 129-139.	0.9	5
114	SHP2 and UGP2 are Biomarkers for Progression and Poor Prognosis of Gallbladder Cancer. <i>Cancer Investigation</i> , 2016, 34, 255-264.	0.6	22
115	The biological function of SHP2 in human disease. <i>Molecular Biology</i> , 2016, 50, 22-27.	0.4	13
116	Current Status of PTP-Based Therapeutics. , 2016, , 335-353.		1
117	Oxindole: A chemical prism carrying plethora of therapeutic benefits. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 858-894.	2.6	231
118	C-terminal Src kinase-mediated <sc>EPIYA</sc> phosphorylation of Pragmin creates a feed-forward C-terminal Src kinase activation loop that promotes cell motility. <i>Cancer Science</i> , 2016, 107, 972-980.	1.7	38
119	Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway. <i>Science Signaling</i> , 2016, 9, rs6.	1.6	119
120	Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. <i>Nature</i> , 2016, 539, 304-308.	13.7	210
121	Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. <i>Nature</i> , 2016, 535, 148-152.	13.7	674
122	The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42. <i>Nature Communications</i> , 2016, 7, 10420.	5.8	6
123	An Introduction to Signal Transduction. , 2016, , 53-183.		1
124	Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma. <i>Tumor Biology</i> , 2016, 37, 7853-7859.	0.8	20
125	Inhibitors of Protein Tyrosine Phosphatase 1B from Marine Natural Products. <i>Chemistry and Biodiversity</i> , 2017, 14, e1600462.	1.0	15
126	Nuclear Shp2 directs normal embryo implantation via facilitating the ERK tyrosine phosphorylation by the Src kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4816-4821.	3.3	31
127	Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation. <i>Cell Death and Disease</i> , 2017, 8, e2767-e2767.	2.7	44
128	Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells. <i>Cell Death and Disease</i> , 2017, 8, e2765-e2765.	2.7	25
129	Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. <i>Cell Reports</i> , 2017, 18, 2932-2942.	2.9	28
130	Understanding and Resetting Radiation Sensitivity in Rectal Cancer. <i>Annals of Surgery</i> , 2017, 266, 610-616.	2.1	16

#	ARTICLE	IF	CITATIONS
131	CCL3 is a key mediator for the leukemogenic effect of Ptpn11-activating mutations in the stem-cell microenvironment. <i>Blood</i> , 2017, 130, 1471-1474.	0.6	6
132	SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer. <i>Scientific Reports</i> , 2017, 7, 17597.	1.6	25
133	Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10205-10219.	2.9	85
134	Identification of protein tyrosine phosphatase SHP-2 as a new target of perfluoroalkyl acids in HepG2 cells. <i>Archives of Toxicology</i> , 2017, 91, 1697-1707.	1.9	7
135	Dietary quercetin potentiates the antiproliferative effect of interferon- β in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase. <i>Oncotarget</i> , 2017, 8, 113734-113748.	0.8	36
136	An aggressive multifocal primary CNS histiocytosis with <i>PTPN11</i> (Shp2) mutation. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 240-243.	1.8	3
137	Stepping out of the shadows: Oncogenic and tumor-promoting protein tyrosine phosphatases. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 96, 135-147.	1.2	29
138	Protein Tyrosine Phosphatases as Potential Regulators of STAT3 Signaling. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2708.	1.8	124
139	Intramolecular energies of the cytotoxic protein CagA of <i>Helicobacter pylori</i> as a possible descriptor of strains' pathogenicity level. <i>Computational Biology and Chemistry</i> , 2018, 76, 17-22.	1.1	3
140	Regulation of Brain-Derived Neurotrophic Factor and Growth Factor Signaling Pathways by Tyrosine Phosphatase Shp2 in the Retina: A Brief Review. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 85.	1.8	22
141	Prognostic Value of Phosphotyrosine Phosphatases in Hepatocellular Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 2335-2346.	1.1	23
142	De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. <i>Nature Communications</i> , 2018, 9, 1770.	5.8	38
143	Cytotoxic activity of Shp2 inhibitor fumosorinone in human cancer cells. <i>Oncology Letters</i> , 2018, 15, 10055-10062.	0.8	7
144	Rational design of a SHP-2 targeted, fluorogenic peptide substrate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2452-2454.	1.0	0
145	The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5897-5906.	1.0	13
146	Chemical activation of divergent protein tyrosine phosphatase domains with cyanine-based biarsenicals. <i>Scientific Reports</i> , 2019, 9, 16148.	1.6	6
147	A novel anti-melanoma SRC-family kinase inhibitor. <i>Oncotarget</i> , 2019, 10, 2237-2251.	0.8	13
148	Negative regulators of STAT3 signaling pathway in cancers. <i>Cancer Management and Research</i> , 2019, Volume 11, 4957-4969.	0.9	37

#	ARTICLE	IF	CITATIONS
149	Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2571-2592.	2.4	19
150	Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling. <i>Nature Communications</i> , 2019, 10, 1473.	5.8	71
151	A Ceⁱⁱⁱ complex potently inhibits the activity and expression of tyrosine phosphatase SHP-2. <i>Dalton Transactions</i> , 2019, 48, 17673-17682.	1.6	3
152	The Impact of PI3&kinase/RAS Pathway Cooperating Mutations in the Evolution of <i>KMT2A</i>&rearranged Leukemia. <i>HemaSphere</i> , 2019, 3, e195.	1.2	9
153	The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer. <i>Current Pharmaceutical Design</i> , 2019, 24, 3767-3777.	0.9	38
154	Platelet Shp2 negatively regulates thrombus stability under high shear stress. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 220-231.	1.9	9
155	Probing the Dynamic Mechanism of Uncommon Allosteric Inhibitors Optimized to Enhance Drug Selectivity of SHP2 with Therapeutic Potential for Cancer Treatment. <i>Applied Biochemistry and Biotechnology</i> , 2019, 188, 260-281.	1.4	11
156	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. <i>Nature Communications</i> , 2019, 10, 224.	5.8	66
157	A Deregulated PI3K-AKT Signaling Pathway in Patients with Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 35-41.	0.6	40
158	Development and structure-activity relationship study of SHP2 inhibitor containing 3,4,6-trihydroxy-5-oxo-5H-benzo[7]annulene. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126756.	1.0	9
159	Targeting SHP2 as a promising strategy for cancer immunotherapy. <i>Pharmacological Research</i> , 2020, 152, 104595.	3.1	101
160	From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14780-14804.	2.9	16
161	Interaction of the Hippo Pathway and Phosphatases in Tumorigenesis. <i>Cancers</i> , 2020, 12, 2438.	1.7	24
162	Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. <i>Cancer Research</i> , 2020, 80, 4840-4853.	0.4	49
163	Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations. <i>Frontiers in Chemistry</i> , 2020, 8, 597495.	1.8	5
164	Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11368-11396.	2.9	128
165	A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). <i>Journal of Biological Chemistry</i> , 2020, 295, 3563-3575.	1.6	16
166	Pathogenic <i>PTPN11</i> variants involving the poly&glutamine Gln ²⁵⁵ &Gln ²⁵⁶ &Gln ²⁵⁷ stretch highlight the relevance of helix B in SHP2's functional regulation. <i>Human Mutation</i> , 2020, 41, 1171-1182.	1.1	3

#	ARTICLE	IF	CITATIONS
167	Shp2 activation in bone marrow microenvironment mediates the drug resistance of B-cell acute lymphoblastic leukemia through enhancing the role of VCAM-1/VLA-4. <i>International Immunopharmacology</i> , 2020, 80, 106008.	1.7	11
168	Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. <i>European Journal of Medicinal Chemistry</i> , 2020, 190, 112117.	2.6	55
169	Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 13-29.	5.7	74
170	PECAM-1 supports leukocyte diapedesis by tension-dependent dephosphorylation of VE-cadherin. <i>EMBO Journal</i> , 2021, 40, e106113.	3.5	22
171	Targeting SHP2 as a therapeutic strategy for inflammatory diseases. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113264.	2.6	19
172	Strategies to overcome drug resistance using SHP2 inhibitors. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3908-3924.	5.7	18
173	Enhancement of Endothelialization by Topographical Features Is Mediated by PTP1B-Dependent Endothelial Adherens Junctions Remodeling. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 2661-2675.	2.6	8
174	New Scope of Targeted Therapies in Lung Carcinoma. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 629-639.	1.1	1
175	Functional interrogation and therapeutic targeting of protein tyrosine phosphatases. <i>Biochemical Society Transactions</i> , 2021, 49, 1723-1734.	1.6	15
176	JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1 β . <i>Blood Advances</i> , 2021, , .	2.5	3
177	Studies on molecular mechanism between SHP2 and pyridine derivatives by 3D-QSAR, molecular docking and MD simulations. <i>Journal of Saudi Chemical Society</i> , 2021, 25, 101346.	2.4	4
178	Biological Evaluation of Aminobenzoic Acid Derivatives against SHP2. <i>Hans Journal of Medicinal Chemistry</i> , 2021, 09, 87-93.	0.0	0
179	CagA. , 2016, , 33-47.		2
181	Simulating EGFR-ERK Signaling Control by Scaffold Proteins KSR and MP1 Reveals Differential Ligand-Sensitivity Co-Regulated by Cbl-CIN85 and Endophilin. <i>PLoS ONE</i> , 2011, 6, e22933.	1.1	9
182	Functional Short Tandem Repeat Polymorphism of PTPN11 and Susceptibility to Hepatocellular Carcinoma in Chinese Populations. <i>PLoS ONE</i> , 2014, 9, e106841.	1.1	9
183	Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. <i>Oncotarget</i> , 2020, 11, 265-281.	0.8	27
184	A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. <i>Oncotarget</i> , 2016, 7, 18295-18308.	0.8	51
185	SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability & via the PI3K/AKT/GSK3 β signaling pathway. <i>Cancer Biology and Medicine</i> , 2020, 17, 707-725.	1.4	42

#	ARTICLE	IF	CITATIONS
186	Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis. <i>Current Cancer Drug Targets</i> , 2014, 14, 567-588.	0.8	58
187	Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. <i>Cellular Oncology</i> , 2010, 32, 361-72.	1.9	48
188	Protein Tyrosine Phosphatases: New Markers and Targets in Oncology?. <i>Current Oncology</i> , 2008, 15, 5-8.	0.9	21
189	Role of <i>Helicobacter pylori</i> virulence factor cytotoxin-associated gene A in gastric mucosa-associated lymphoid tissue lymphoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 8219.	1.4	29
191	Discovery of 6-[(3 <i>S</i> ,4 <i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15141-15169.	2.9	16
192	Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 753244.	1.3	2
193	Frs2 alpha. <i>The AFCS-nature Molecule Pages</i> , 0, , .	0.2	0
194	Frequency of Human Disease Mutations and Spermatogonial Stem Cell Function. , 2017, , 181-204.		0
199	Elevated hippocampal CD24 in astrocytes participates in neural regeneration possibly via activating SHP2/ERK pathway after experimental traumatic brain injury in mice. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 6395-6408.	0.0	0
200	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 5722.	1.7	17
201	Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5956.	1.7	13
202	Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors. <i>RSC Medicinal Chemistry</i> , 2022, 13, 246-257.	1.7	11
203	Structure-based discovery of a specific SHP2 inhibitor with enhanced blood-brain barrier penetration from PubChem database. <i>Bioorganic Chemistry</i> , 2022, 121, 105648.	2.0	1
204	Shp2 in uterine stromal cells critically regulates on time embryo implantation and stromal decidualization by multiple pathways during early pregnancy. <i>PLoS Genetics</i> , 2022, 18, e1010018.	1.5	8
205	Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. <i>Journal of Biological Chemistry</i> , 2022, 298, 101477.	1.6	6
206	Inhibition of SHP2 as an approach to block RAS-driven cancers. <i>Advances in Cancer Research</i> , 2022, 153, 205-236.	1.9	7
207	Endothelial cells promote the proliferation and migration of Schwann cells. <i>Annals of Translational Medicine</i> , 2022, 10, 78-78.	0.7	8
208	Retinal SHP2 silencing alleviates diabetic retinopathy via suppressing inflammatory response and oxidative stress by regulating YAP1 activity. <i>Experimental Animals</i> , 2022, , .	0.7	0

#	ARTICLE	IF	CITATIONS
209	Accurate calculation of absolute free energy of binding for SHP2 allosteric inhibitors using free energy perturbation. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 9904-9920.	1.3	2
210	Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3066-3079.	2.9	41
211	Proteolysis-targeting chimera molecules targeting SHP2. <i>Future Medicinal Chemistry</i> , 2022, 14, 587-600.	1.1	4
212	PTPN11 Gene Mutations and Its Association with the Risk of Congenital Heart Disease. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	5
213	Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization. <i>ACS Omega</i> , 2022, 7, 14180-14188.	1.6	4
215	Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6729-6747.	2.9	7
217	Mutation of PTPN11 (Encoding SHP-2) Promotes MEK Activation and Malignant Progression in Neurofibromin-Deficient Cells in a Manner Sensitive to BRAP Mutation. <i>Cancers</i> , 2022, 14, 2377.	1.7	1
218	Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery. <i>Medicinal Research Reviews</i> , 2022, 42, 1781-1821.	5.0	14
219	Dichotomous role of Shp2 for naïve and primed pluripotency maintenance in embryonic stem cells. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	2
220	Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells. <i>Nature Communications</i> , 2022, 13, .	5.8	22
221	Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
222	Comparative proteomic analysis of insulin receptor isoform A and B signaling. <i>Molecular and Cellular Endocrinology</i> , 2022, 557, 111739.	1.6	2
223	A comprehensive review of SHP2 and its role in cancer. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 729-753.	2.1	32
224	An Integrated Proteomic Strategy to Identify SHP2 Substrates. <i>Journal of Proteome Research</i> , 2022, 21, 2515-2525.	1.8	4
225	Germline selection of PTPN11 (HGNC:9644) variants make a major contribution to both Noonan syndrome's high birth rate and the transmission of sporadic cancer variants resulting in fetal abnormality. <i>Human Mutation</i> , 2022, 43, 2205-2221.	1.1	4
226	Discovery of allosteric SHP2 inhibitors through ensemble-based consensus molecular docking, endpoint and absolute binding free energy calculations. <i>Computers in Biology and Medicine</i> , 2023, 152, 106442.	3.9	2
227	From Stem to Sternum: The Role of Shp2 in the Skeleton. <i>Calcified Tissue International</i> , 0, , .	1.5	1
228	Layered immunity and layered leukemogenicity: Developmentally restricted mechanisms of pediatric leukemia initiation. <i>Immunological Reviews</i> , 2023, 315, 197-215.	2.8	3

#	ARTICLE	IF	CITATIONS
229	Targeting SHP2 for Cancer Treatment: Advances and Prospects. , 2023, , 1-19.		0
230	Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review). Oncology Reports, 2023, 49, .	1.2	5
231	RAS pathway: The new frontier of brain mosaicism in epilepsy. Neurobiology of Disease, 2023, 180, 106074.	2.1	3
232	Setting sail: Maneuvering SHP2 activity and its effects in cancer. Advances in Cancer Research, 2023, , .	1.9	0
234	Exploring Allosteric Inhibitors of Protein Tyrosine Phosphatases Through High-Throughput Screening. Methods in Molecular Biology, 2023, , 235-245.	0.4	0
243	Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors. International Review of Cell and Molecular Biology, 2024, , .	1.6	0